Accelerated shelf life testing: how it works and how to calculate it

What is the difference between accelerated and real-time stability testing?

A real-time, or long-term, study keeps the product at the conditions it will meet in normal storage and tests it at intervals through the end of the intended shelf life. An accelerated study keeps the same product at exaggerated conditions, usually higher temperature and humidity, so chemical change shows up sooner. ICH Q1A(R2) describes accelerated testing as studies "designed to increase the rate of chemical degradation or physical change of a drug substance or drug product by using exaggerated storage conditions", and adds: "Results from accelerated testing studies are not always predictive of physical changes."

Real-time and accelerated studies compared.

How do Q10 and the Arrhenius equation turn heat into time?

The Arrhenius equation describes how the rate of a chemical reaction rises with temperature. In plain words, the rate grows exponentially as the temperature goes up, and how steeply it grows depends on the reaction's activation energy, a property of that particular breakdown pathway. ICH Q1A(R2) uses the same idea in its definition of mean kinetic temperature, which "takes into account the Arrhenius equation."

Shelf life work often uses a simpler rule of thumb called Q10: the factor by which a reaction speeds up for every 10°C rise in temperature. With a Q10 of 2, each 10°C step doubles the rate. The acceleration factor between the test temperature and the storage temperature is Q10 raised to the power of (test temperature minus storage temperature) ÷ 10. Multiply the time spent at the test temperature by that factor to estimate the equivalent time at the storage temperature.

What does a worked accelerated shelf life calculation look like?

These numbers are illustrative only and do not describe any real product. A vitamin tablet stays within its potency specification for 6 months at 40°C. The brand plans normal storage at 25°C and assumes a Q10 of 2.

1. Temperature difference: 40°C minus 25°C = 15°C.
2. Acceleration factor: 2 raised to the power of 15 ÷ 10, that is 2 to the power 1.5, which is about 2.83.
3. Estimated equivalent time at 25°C: 6 months × 2.83 = about 17 months.

Illustrative calculation, not data: how the assumed Q10 changes the estimate from 6 months at 40°C to storage at 25°C.

The same 6 months of data can be read as anything from about 11 to about 31 months, depending on a single assumption. That is why Q10 should come from the product's own data where possible, for example from results at two or more elevated temperatures, and why the answer is treated as a provisional date. The calculation also ignores humidity, which drives many supplement failures, and it cannot predict physical changes such as softening or leaking that only happen at high temperature.

What storage conditions does ICH Q1A(R2) set?

ICH Q1A(R2) is the stability guideline for new drug substances and drug products. Its general case for drug products is:

ICH Q1A(R2) Stability Testing of New Drug Substances and Products, section 2.2.7.1, general case for drug products (Step 4 version dated 6 February 2003).

Figures checked against the sources below on 3 November 2026; rules change, so confirm the current version before relying on them.

The applicant chooses which long-term condition to use, and "If 30°C ± 2°C/65% RH ± 5% RH is the long-term condition, there is no intermediate condition." For long-term studies, ICH recommends testing "every 3 months over the first year, every 6 months over the second year, and annually thereafter", and for the accelerated condition "a minimum of three time points, including the initial and final time points (e.g., 0, 3, and 6 months)". On how far data can be stretched, the companion guideline ICH Q1E says that where long-term and accelerated data show little or no change and little variability, "The proposed retest period or shelf life can be up to twice, but should not be more than 12 months beyond, the period covered by long-term data."

These guidelines are written for medicines. No federal rule requires dietary supplements to follow them, but many supplement brands use Q1A conditions as guidance because they are clearly defined. ICH is also replacing Q1A(R2) with a consolidated Q1 guideline; its February 2026 work plan targets Step 4 adoption in November 2026, so check ich.org for the version in force.

How do expiration dates relate to accelerated data?

FDA does not require an expiration date on a dietary supplement, but any date you print should be supported by data; the stability testing page covers that rule. Accelerated results give a provisional estimate to support a first date, and real-time data collected at the labeled storage condition should confirm or replace it as it comes in.

What should be tested at each pull point?

Attributes commonly tracked in supplement stability studies.

Test every attribute at time zero so later results have a baseline, and use the same methods at every pull point so a change reflects the product rather than the method. Then compare each result with the acceptance criteria written into the protocol before the study started. We test stability samples at each pull point for the attributes in your protocol; potency is covered on potency and assay testing, microbial counts on microbiology testing, and moisture and water activity on nutrition and composition testing.

Questions about this page

Sources: ICH Q1A(R2) Stability Testing of New Drug Substances and Products (Step 4, 6 February 2003) · ICH Q1E Evaluation of Stability Data (Step 4, 6 February 2003) · ICH Q1 Expert Working Group work plan (February 2026) · FDA Small Entity Compliance Guide: CGMP in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements · 21 CFR 111.83: Reserve samples (eCFR)
Last reviewed: 3 November 2026